These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2403227)

  • 1. A comparative immunogenicity-reactogenicity dose-response study of influenza vaccine.
    Guarnaccia S; Peters SM; Habib F; Mancuso GR; Dibenedetto SP; Espey M; Bellanti JA
    Ann Allergy; 1990 Sep; 65(3):218-21. PubMed ID: 2403227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults.
    Langley JM; Halperin SA; McNeil S; Smith B; Jones T; Burt D; Mallett CP; Lowell GH; Fries L
    Vaccine; 2006 Mar; 24(10):1601-8. PubMed ID: 16303215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza immunization in children and young adults: clinical reactions and total and IgM antibody responses after immunization with whole-virus or split-product influenza vaccines.
    Bernstein DI; Zahradnik JM; DeAngelis CJ; Cherry JD
    Am J Dis Child; 1982 Jun; 136(6):513-7. PubMed ID: 7046421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with inactivated, virosomal influenza vaccine.
    de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
    Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprophylaxis for influenza: comparison of a subunit and a whole virion vaccine.
    Carle F; Bolgiani M; Zanon P; Moiraghi Ruggenini A; Zotti C
    Boll Ist Sieroter Milan; 1988; 67(2):105-15. PubMed ID: 3067735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA; Walter EB; Fairchok MP; Monto AS; Neuzil KM
    Pediatrics; 2005 Apr; 115(4):1039-47. PubMed ID: 15805382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.
    Hanania NA; Sockrider M; Castro M; Holbrook JT; Tonascia J; Wise R; Atmar RL;
    J Allergy Clin Immunol; 2004 Apr; 113(4):717-24. PubMed ID: 15100679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal DNA vaccine for influenza is immunogenic in humans.
    Drape RJ; Macklin MD; Barr LJ; Jones S; Haynes JR; Dean HJ
    Vaccine; 2006 May; 24(21):4475-81. PubMed ID: 16150518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
    Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
    Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
    J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM; Camilloni B; Basileo M; Neri M; Lepri E; Spighi M
    Gerontology; 2007; 53(6):411-8. PubMed ID: 17975317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
    Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity.
    Chalmers A; Scheifele D; Patterson C; Williams D; Weber J; Shuckett R; Teufel A
    J Rheumatol; 1994 Jul; 21(7):1203-6. PubMed ID: 7966058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.